Abstract:Objective: To explore commonalities and differences in the sociodemographic, health, and neuropsychological characteristics of participants with SCD recruited in two culturally differentiated cohort studies, namely CIMA-Q (Canada; Bellevile et al., 2019) and CompAS (Spain; Juncos et al., 2012). Methods: Older adults with subjective cognitive complaints of the CompAS (N=251; 68.92% women; Control: 30.3%; SCD: 25.9%; MCI: 28.7%) and the CIMA-Q (N=179; 71.5% women; Control:16.1%; SCD: 36.8%; MCI:28.6%) were recruited, respectively, from primary care centers and memory clinics, excluding patients with dementia and other neurological or psychiatric disturbances. Cognitive complaints were assessed considering coincident items of the QAM and MFE questionnaires. Cut-off points for the 5%ile were calculated independently in both samples and according to this, participants were classified as SCD or controls (CompAS: N= 141; CIMA-Q: N=161) considering complaints relevance at baseline (Pereiro et al., 2021). Participants underwent neuropsychological assessment. Participants diagnosed as Mild Cognitive Impairment (MCI) were excluded from the analysis. Between cohort-studies and inter-group (control, SCD) differences were tested in the sociodemographic, health and neuropsychological measures considered. The Holm-Bonferroni correction was applied to reduce the probability of type I error (p<.003). Results: Identical cut-off points for 5%ile were obtained in both samples though SCD prevalence was slightly higher in CIMA-Q. For both samples, equivalence between Control and SCD participants in sociodemographic, health, functionality, and neuropsychological measures was observed. Only complaints and depressive symptomatology was significantly higher in SCD participants than in controls in both CompAS and CIMA-Q studies. Participants of the CIMA-Q, Controls and SCD, showed significantly higher age, cognitive reserve proxies, comorbidity, and better attentional performance than the CompAS participants (see Table 1). CompAS participants, Controls and SCD, showed more neuropsychiatric symptomatology than CIMA-Q participants (see Table 1). Conclusions: Control and SCD participants showed equivalence on sociodemographic, health, functional, and neuropsychological measures in both studies. However, significant between-sample differences in the two groups, particularly in SCD participants, were observed in sociodemographic, health, cognitive reserve, behavioral and attentional measures. Identification of these factors are critical to analyze the transcultural validity of cognitive complaints in predicting progression to AD. Table 1 Between group (control, SCD) and Between study (CIMA-Q, CompAS) differences in sociodemographic, health, and cognitive measures CIMA-Q CompAS Between-studies differences Between-group differences Between-group differences Control SCD Sociodemographics Age NS NS CIMA-Q>CompAS; F(1,124)=22.78; p<.001 CIMA-Q>CompAS; F(1,172)=36.97; p<.001 Gender NS NS NS NS Schooling (years) NS NS NS CIMA-Q>CompAS; F(1,172)=20.74; p<.001 Prof. qualification NS NS CIMA-Q>CompAS; χ 2 4 =18.18; p=001 CIMA-Q>CompAS; χ 2 4 =33.95; p<001 Cognitive reserve (quartiles) NS NS CIMA-Q>CompAS; χ 2 3 =13.57; p=004 CIMA-Q>CompAS;χ 2 3 ==42.56; p<001 Memory familiar antecedents NS NS NS CIMA-Q>CompAS; χ 2 1 ==15.03; p<001 Neuropsychology Subjective complaints* SCD>Control; F(1,119)=147.17, p<.001) SCD>Control; F(1,177)=192.87, p<.001 NS NS Charlson Index* SCD>Control; F(1,115)=5.29, p=.023 NS CIMA-Q>CompAS; F(1,123)=394.96; p<.001 CIMA-Q>CompAS; F(1,168)=335.98; p<.001 General cognition NS (MoCA) NS (CAMCOG-R) -- -- GDS-15* SCD>Control; F(1,119)=8.60, p=.004 SCD>Control; F(1,176)=11.97, p<.001 NS NS TMT-A (secs.)* NS NS NS NS TMT-B (secs.)* NS NS CompAS>CIMA-Q; F(1,118)=12.56; p<.001 CompAS>CIMA-Q; F(1,163)=21.74; p<.001 Verbal fluency NS NS NS NS Semantic fluency N -Abstract Truncated-

The effect of years of schooling and age on CERAD-MX performance in Mexican preclinical carriers of the APP V717I mutation: Randomized data simulation

The effect of age and years of schooling on CERAD‐MX performance of Mexican preclinical carriers and non‐carriers’ relatives of the V717I APP mutation

F4‐04‐02: AGE‐RELATED CHANGES IN BASELINE COGNITIVE MEASURES IN UNIMPAIRED PSEN1 E280A MUTATION CARRIERS AND NON‐CARRIERS IN THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL

ASSOCIATION BETWEEN CEREBRAL AMYLOIDOSIS AND WORSE COGNITIVE PERFORMANCE IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: BASELINE FINDINGS FROM THE API COLOMBIA AUTOSOMAL DOMINANT AD TRIAL

P3-287: Composite Cognitive Endpoints with Improved Power to Detect Presymptomatic Alzheimer's Disease Treatment Effects: Findings in the Colombian Kindred with the E280A Presenilin 1 Mutation and the Alzheimer's Prevention Initiative

P4‐269: Relationships Between Baseline Biomarkers and Subsequent Cognitive Decline in Cognitively Unimpaired PSEN1 E280A Mutation Carriers from the Colombian Kindred with Autosomal Dominant Alzheimer's Disease

IC‐P‐017: Trajectory of Age‐associated Structural Changes in Early‐onset Alzheimer's Disease, for the Alzheimer's Prevention Initiative

The Alzheimer'S Prevention Initiative Composite Cognitive Test Score: Sample Size Estimates For The Evaluation Of Preclinical Alzheimer'S Disease Treatments In Presenilin 1 E280a Mutation Carriers

Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease

COGNITIVE VULNERABILITIES IN PRESENILIN-1 E280A MUTATION-CARRYING CHILDREN FROM THE WORLD’S LARGEST AUTOSOMAL-DOMINANT ALZHEIMER’S DISEASE KINDRED

RELATIONSHIPS BETWEEN BASELINE BRAIN IMAGING BIOMARKER MEASUREMENTS AND AGE IN THE API AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE COLOMBIA TRIAL

[O1–13–02]: COGNITIVE VULNERABILITIES IN PRESENILIN‐1 E280A MUTATION‐CARRYING CHILDREN FROM THE WORLD's LARGEST AUTOSOMAL‐DOMINANT ALZHEIMER's DISEASE KINDRED

Reproductive Health Data and Its Relationship to Baseline Brain Imaging and Cognitive Measurements in Cognitively Unimpaired Female PSEN1 E280A Mutation Carriers and Non‐carriers from the API ADAD Trial

IC‐O1–01: Pre‐symptomatic Functional Brain Changes in PS1 E280A Mutation Carriers Compared to Other Biomarkers: Pilot Data from the Alzheimer's Prevention Initiative Biomarker Project

Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation

Sex Differences in Cognitive Resilience in Preclinical Autosomal-Dominant Alzheimer's Disease Carriers and Non-Carriers: Baseline Findings from the API ADAD Colombia Trial

[P2–434]: INTELLECTUAL FUNCTION VERSUS YEARS OF EDUCATION AS COGNITIVE RESERVE PROXIES: INTERACTION WITH ALZHEIMER's DISEASE NEUROPATHOLOGY AND IMPACT ON EPISODIC MEMORY AND EXECUTIVE FUNCTION

The MAPP Room Memory Test: Examining Contextual Memory Using a Novel Computerized Test in Cognitively-Unimpaired Individuals with Autosomal Dominant Alzheimer’s Disease

P1-259: Regional Hypometabolism in Cognitively Normal Hispanic Carriers of the Apolipoprotein E-ϵ4 Allele

P4–068: Pre‐symptomatic Functional Brain Changes in PS1 E280A Mutation Carriers Compared with Other Biomarkers: Pilot Data from the Alzheimer's Prevention Initiative Biomarker Project

P153: The CIMA-Q and CompAS cohort studies on factors associated with Alzheimer's disease (AD): Exploring sociodemographic, health and neuropsychological profile of Subjective Cognitive Decline (SCD) participants from two culturally differentiated samples.